Initiation (new start) criteria and criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary risankizumab-rzzaa (Skyrizi) will be covered on the prescription drug benefit for when the following criteria are met:

1. Prescriber is a dermatologist and patient has a diagnosis of plaque psoriasis
   - Patient has tried and failed/intolerant to at least 1 of the following:
     - Infliximab product
     - Adalimumab (criteria based)
     - Etanercept (criteria based)
   - Patient has tried and failed/intolerant to or has a contraindication to secukinumab (criteria based)